A Cambridge biotech that’s working on drugs to reverse kidney disease — rather than merely slow its progression ― was unveiled Tuesday after raising $51 million in venture capital.
Walden Biosciences was created by Chicago-based ARCH Venture Partners and UCB Ventures, of Belgium. Both venture capital firms funnel early-stage funding to promising startups.
